Form 4: ALXO CFO Buys 75,000 Shares

ALX Oncology Holdings Inc.'s Chief Financial Officer, Harish Shantharam, acquired 75,000 shares of common stock.

Summary

• Harish Shantharam, Chief Financial Officer of ALX Oncology Holdings Inc. (ALXO), purchased 75,000 shares of the company's common stock.
• The transaction occurred on August 18, 2025.
• The shares were acquired at a weighted average price of $0.7787 per share.
• Individual purchase prices for the shares ranged from $0.6823 to $0.9234 per share.
• Following this transaction, Mr. Shantharam directly owns 75,000 shares of ALX Oncology Holdings Inc. common stock.

Sentiment

Score: 8

Explanation: The acquisition of a substantial number of shares by a key executive like the CFO is a strong positive signal, indicating internal confidence in the company's future performance and valuation.

Positives

• A key executive, the Chief Financial Officer, is increasing their direct ownership in the company, signaling confidence in future prospects.
• The purchase of 75,000 shares represents a significant investment by an insider.

Future Outlook

NA

Industry Context

Insider purchases, especially by a Chief Financial Officer, can be viewed positively in the biotechnology and oncology sectors as they may indicate management's belief in the company's pipeline, clinical trial progress, or future commercialization potential, despite the inherent risks of drug development.

Related Party Transactions

• The transaction involves the Chief Financial Officer purchasing shares from the company, which is a direct related-party transaction as an insider acquisition.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management's belief in the company's value, potentially increasing investor confidence.
• Employees may see this as a sign of stability and positive outlook from leadership.

Key Dates

Recommendation

The Chief Financial Officer's significant share purchase signals strong internal confidence in ALX Oncology Holdings Inc.'s future. While this is a positive indicator, a comprehensive investment decision requires evaluating broader financial performance, strategic initiatives, and market conditions beyond the scope of this single insider transaction report.

Keywords

ALX Oncology Holdings Inc., ALXO, Harish Shantharam, Chief Financial Officer, CFO, Insider Trading, Stock Purchase, Common Stock, SEC Form 4, Biotechnology, Oncology